Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

EFS of Posterior Leaflet Replacement to Reduce Mitral Regurgitation (United States)

NCT: NCT07517588 · NOT_YET_RECRUITING

NCT IDNCT07517588
StatusNOT_YET_RECRUITING
Start Date2026-06-01
Completion2031-12-31

Brief Summary

The goal of this early feasibility clinical trial is to learn if the device MR-ace Implant and Delivery System works in patients with moderate or severe mitral valve regurgitation. It will also learn about the safety of the device MR-ace Implant and Delivery System. The main questions it aims to answer are: Does implanting the MR-ace device reduce the symptoms of mitral regurgitation? Does the device reduce the the leak through your mitral valve? Participants will: Be implanted with the device Visit the clinic for checkups and tests at 30 days, 6 months, 12 months, and 2, 3, 4 and 5 years following your procedure Complete a quality of life survey

Frequently Asked Questions

What is EFS of Posterior Leaflet Replacement to Reduce Mitral Regurgitation (United States)?

EFS of Posterior Leaflet Replacement to Reduce Mitral Regurgitation (United States) is a clinical trial registered under NCT07517588. Current status: NOT_YET_RECRUITING.

What is the status of NCT07517588?

The current status of NCT07517588 (EFS of Posterior Leaflet Replacement to Reduce Mitral Regurgitation (United States)) is: NOT_YET_RECRUITING.

When did EFS of Posterior Leaflet Replacement to Reduce Mitral Regurgitation (United States) start?

EFS of Posterior Leaflet Replacement to Reduce Mitral Regurgitation (United States) started on 2026-06-01.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑